This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
"But the model that we have is on the opposite end of the spectrum, where the idea is that the theranostics physicians, whether they're nuclear medicine physicians or radiologists, actually temporarily become the patient's subspecialty medical oncologist," Siegel said. "As led by Harshad Kulkarni, MD, as principal investigator.
Recognizing the industry transformation taking place as digital innovation reshapes the experience of patients and providers, GE HealthCare – a leading global medical technology, pharmaceutical diagnostics, and digital innovator – is focused on developing smart devices, aligned to disease states and enabled by digital.
announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio. Together, we'll strive to continue our shared legacy of enhancing patientcare.
Mark Hibberd, Chief Medical Officer at GE HealthCare’s Pharmaceutical Diagnostics segment, said. Detecting ER+ lesions in patients with recurrent or metastatic breast cancer could potentially aid oncologists, surgeons and clinicians in choosing the most appropriate therapy for patients.”
At the center of the collaboration, the companies will integrate Nucleai’s predictive biomarker solutions into Proscia’s Concentriq software platform and make them available as part of Proscia’s precision medicine AI portfolio to better inform patientcare. Along with today’s news, Nucleai joins the Proscia Ready partner alliance.
Cardiovascular care has seen remarkable advancements over the decades, from innovative surgical techniques to cutting-edge pharmaceuticals. Despite these strides, treatment pathways are often plagued by inefficiencies, administrative burdens and even care disparities. Yet, challenges remain.
Imagine going in for a diagnostic MRI scan and coming out with a progressive, irreversible, and potentially fatal disease. That's what has happened to hundreds of people worldwide who have developed nephrogenic systemic fibrosis (NSF), an acquired disorder in renal patients that's been classified only since 2000. In 2006 the U.S.
For those unfamiliar with steatotic liver disease, this is important because Rezdiffra is the first approved treatment for MASH, which if left untreated can progress to cirrhosis, require liver transplantation, and potentially cause death. Rajarshi Banerjee, MD, PhD.
Nucleus will use NorthStar’s Ac-225 for their customers’ radioligand pharmaceutical programs. Ac-225 carries sufficient radiation to cause cell death in a localized area of targeted cells, while its half-life limits unwanted radioactivity in patients. Ac-225 to Nucleus. Ac-225 that has positioned us at the forefront of U.S.
However, team members were surprised to find the order did not once mention patient outcomes, the standard metric by which healthcare products are judged before being allowed to access the healthcare marketplace. “The goal of medicine is to save lives,” said Davey Smith , M.D., Ayers , Ph.D.,
christine.book Wed, 06/21/2023 - 10:48 June 21, 2023 — NYU Langone Health has published an overview of an artificial intelligence (AI)-powered tool designed to smooth hospital operations for better patientcare. Keck Foundation Medical Research Grant. He also has equity in Artisight Inc.,
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content